2020 article

Efficacy of the DigniCap System in preventing chemotherapy‐induced alopecia in breast cancer patients is not related to patient characteristics or side effects of the device

Rebecca Pedersini, Carla Fornaro, Pierluigi di Mauro, Susanna Bianchi, Lucia Vassalli, Vito Amoroso, Maria Chiara Gelmi, Mara Ardine, Filippo Rodella, Deborah Cosentini, Alberto Dalla Volta, Antonella Turla, Michela Pierini, Paolo Carlo Motta, Elisa Conti, Edda Simoncini, Alfredo Berruti

13Citations signalées, ce qui n’est pas une note de qualité

3Institutions déclarées

2Pays d’affiliation déclarés

Rattachement africain : ca, it. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: The DigniCap System is an effective scalp cooling device for the prevention of chemotherapy-induced alopecia in early breast cancer patients. AIM: This prospective study was designed to confirm the efficacy and tolerability of the device, to explore potential factors associated with its efficacy and to collect data on patient perceptions and satisfaction. METHODS: Between January 2016 and June 2018, 163 early breast cancer patients eligible for adjuvant chemotherapy were enrolled. Hair loss was assessed using the Dean scale, where a score of 0-2 (hair loss ≤50%) was defined as successful. RESULTS: Hair preservation was successful in 57% of patients in the overall series. The proportion was even higher (81%) in the patient subgroup treated with a paclitaxel and trastuzumab regimen. Side effects (feeling cold, headache, head heaviness, scalp and cervical pain) were mild to moderate and did not correlate with the rate of hair loss. Lifestyle, anthropometric factors and hair characteristics failed to be associated with device efficacy. CONCLUSIONS: The DigniCap System was well tolerated and found to be effective in preventing alopecia in early breast cancer patients. Our study failed to identify factors other than type of chemotherapy regimen associated with hair preservation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref: Efficacy of the DigniCap System in preventing chemotherapy‐induced alopecia in breast cancer patients is not related to patient characteristics or side effects of the device
Date Crossref: 22/09/2020
Éditeur: Wiley
Type: journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

Surgical Specialties (Canada) pays non établi dans la notice
Entreprise
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia pays non établi dans la notice
Établissement de santé
University of Brescia Department of Medical and Surgical Specialties pays non établi dans la notice
Université ou école supérieure
Breast Unit‐Medical Oncology ASST Spedali Civili Brescia Italy pays non établi dans la notice
Institution
Breast Unit-Medical Oncology pays non établi dans la notice
Institution
Breast Unit ASST Spedali Civili Brescia Italy pays non établi dans la notice
Institution

Surgical Specialties (Canada), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia et Department of Medical and Surgical Specialties — University of Brescia, avec 3 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Hair Growth and DisordersOral health in cancer treatmentChemotherapy-related skin toxicity

Consulter la publication primaire Ouvrir le DOI